Revenue: $145,000; YoY growth: 624.09%; QoQ change: -4.15%; Gross Profit: $129,069; Gross Margin: 89.01%; EBITDA: -$636,801; EBITDA Margin: -4.39%; Operating Income: -$668,000; Operating Margin: -4.61%; Net Income: -$649,539; Net Margin: -4.48%; EPS: -$0.0603; Weighted Avg Shares: 10,765,143; Cash Flow from Operations: -$619,614; Free Cash Flow: -$676,604; Net Cash Provided by Financing Activities: $3,452,836; Cash at End of Period: $4,705,399; Total Assets: $6,352,043; Total Liabilities: $204,203; Total Stockholders’ Equity: $6,520,789; Current Ratio: 66.29; Quick Ratio: 66.29; Debt: $148,885; Net Debt: -$4,556,514; Price to Sales: 256.14; Price to Book: 5.70; Enterprise Value Multiple: -51.17; Gross Profit Margin and Margin stability reflect a high gross margin on a tiny revenue base, underscoring DehydraTECH’s potential leverage once commercialization or licensing milestones materialize.